



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

Re: REDUX™  
Docket No. 96E-0265

NOV 2 | 1996

Stephen G. Kunin  
• Deputy Assistant Commissioner for  
Patent Policy and Projects  
U.S. Patent and Trademark Office  
Box Pat. Ext.  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Mr. Kunin:

This is in regard to the application for patent term extension for U.S. Patent No. 4,309,445 filed by Interneuron Pharmaceuticals, Inc. under 35 U.S.C. § 156. The human drug product claimed by the patent is REDUX™ (dexfenfluramine hydrochloride), which was assigned New Drug Application (NDA) No. 20-344.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of this product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp. 1224 (E.D. Va. 1989), aff'd, 894 F.2d 392 (Fed. Cir. 1990).

The NDA was approved on April 29, 1996, which makes the submission of the patent term extension application on June 25, 1996, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A), we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely,

Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs

cc: Charles E. Van Horn  
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.  
1300 I Street, N.W.  
Washington, D.C. 20005-3315